BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...pivotal trial of its lead therapy targeting EBV-positive lymphomas.By merging with Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), Viracta Therapeutics Inc....
...Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase kinase 1 Paul Bonanos VRx-3996, chr-3996, Tractinostat Viracta Therapeutics Inc. Sunesis...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Smethurst will become interim CMO. He succeeds Lisa Rojkjaer, who is joining precision oncology company Viracta Therapeutics Inc....
...Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus...
BioCentury | Aug 2, 2019
Company News

Management tracks: Third Rock-backed Thrive names new CEO; plus PhRMA, Adverum and more

...Don Elsey as CFO. He was CFO of Senseonics Inc. (Germantown, Md.). Viral-associated cancers company Viracta Therapeutics Inc....
BioCentury | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif...
...latent viral proteins that make cancerous cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Viracta Therapeutics Inc....
...Calif. Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294), Guangdong, China Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta Therapeutics Inc. Histone...
BioCentury | Dec 4, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif...
...cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta Therapeutics Inc. Histone...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...Longenecker as interim CEO. Longenecker was president and CEO at HemaQuest Pharmaceuticals Inc., which became Viracta Therapeutics Inc....
BioCentury | Apr 13, 2018
Clinical News

Viracta starts Phase Ib/II of VRx-3996 for Epstein-Barr virus-positive lymphomas

...duration of response, progression-free survival (PFS) and pharmacokinetics. VRx-3996 is an histone deacetylase (HDAC) inhibitor. Viracta Therapeutics Inc....
...duration of response, progression-free survival (PFS) and pharmacokinetics Status: Phase Ib/II started Milestone: NA Alicia Parker VRx-3996, chr-3996 Viracta Therapeutics Inc. Histone...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...syndrome (MDS) Phase I/II $26.5 Amgen Ventures; Clarus; Frazier Healthcare; Merck Research Labs Ventures Fund Viracta Therapeutics Inc....
BioCentury | Apr 7, 2017
Finance

Combo quest

...By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor...
...linked to IL-2 that has completed Phase II in advanced bladder cancer. Virginia Li, Staff Writer VRx-3996 NantKwest Inc. Viracta Therapeutics Inc. HDAC...
BioCentury | Apr 7, 2017
Company News

Viracta, NantKwest deal

...lymphoma. Viracta Therapeutics Inc. , San Diego, Calif. NantKwest Inc. (NASDAQ:NK), San Diego, Calif. Business: Cancer Julian Zhu VRx-3996 NantKwest Inc. Viracta Therapeutics Inc....
Items per page:
1 - 10 of 13
BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...pivotal trial of its lead therapy targeting EBV-positive lymphomas.By merging with Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), Viracta Therapeutics Inc....
...Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase kinase 1 Paul Bonanos VRx-3996, chr-3996, Tractinostat Viracta Therapeutics Inc. Sunesis...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Smethurst will become interim CMO. He succeeds Lisa Rojkjaer, who is joining precision oncology company Viracta Therapeutics Inc....
...Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus...
BioCentury | Aug 2, 2019
Company News

Management tracks: Third Rock-backed Thrive names new CEO; plus PhRMA, Adverum and more

...Don Elsey as CFO. He was CFO of Senseonics Inc. (Germantown, Md.). Viral-associated cancers company Viracta Therapeutics Inc....
BioCentury | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif...
...latent viral proteins that make cancerous cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Viracta Therapeutics Inc....
...Calif. Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294), Guangdong, China Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta Therapeutics Inc. Histone...
BioCentury | Dec 4, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

...Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif...
...cells vulnerable to antiviral treatment (see “Viral Vulnerability” ). Alicia Parker VRx-3996, chr-3996, Tractinostat Shenzhen Salubris Pharmaceuticals Co. Ltd. Viracta Therapeutics Inc. Histone...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...Longenecker as interim CEO. Longenecker was president and CEO at HemaQuest Pharmaceuticals Inc., which became Viracta Therapeutics Inc....
BioCentury | Apr 13, 2018
Clinical News

Viracta starts Phase Ib/II of VRx-3996 for Epstein-Barr virus-positive lymphomas

...duration of response, progression-free survival (PFS) and pharmacokinetics. VRx-3996 is an histone deacetylase (HDAC) inhibitor. Viracta Therapeutics Inc....
...duration of response, progression-free survival (PFS) and pharmacokinetics Status: Phase Ib/II started Milestone: NA Alicia Parker VRx-3996, chr-3996 Viracta Therapeutics Inc. Histone...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...syndrome (MDS) Phase I/II $26.5 Amgen Ventures; Clarus; Frazier Healthcare; Merck Research Labs Ventures Fund Viracta Therapeutics Inc....
BioCentury | Apr 7, 2017
Finance

Combo quest

...By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor...
...linked to IL-2 that has completed Phase II in advanced bladder cancer. Virginia Li, Staff Writer VRx-3996 NantKwest Inc. Viracta Therapeutics Inc. HDAC...
BioCentury | Apr 7, 2017
Company News

Viracta, NantKwest deal

...lymphoma. Viracta Therapeutics Inc. , San Diego, Calif. NantKwest Inc. (NASDAQ:NK), San Diego, Calif. Business: Cancer Julian Zhu VRx-3996 NantKwest Inc. Viracta Therapeutics Inc....
Items per page:
1 - 10 of 13